重组人促红细胞生成素治疗胃肠道恶性肿瘤化疗相关性贫血的临床观察  

Clinical observation of recombinant human erythropoietin on chemotherapy-induced anemia in patients with gastrointestinal cancer

作　　者：赵成民[1] 黄带发[1] 张丽辉[1] 曹玉华[1] 车海龙[1] 

机构地区：[1]沈阳军区总医院干二科,沈阳110016

出　　处：《中国新药杂志》2018年第2期173-177,共5页Chinese Journal of New Drugs

摘　　要：目的:观察重组人促红细胞生成素治疗胃肠道恶性肿瘤相关性贫血的有效性及安全性。方法:选取胃肠道恶性肿瘤化疗后贫血的80例患者,随机分成两组,每组40例。治疗组给予重组人促红细胞生成素及铁剂进行治疗;对照组仅给予铁剂治疗。观察两组的血红蛋白和红细胞变化以及KPS评分和不良反应发生情况。结果:治疗组与对照组临床有效率分别为97.5%和25%,治疗组显著高于对照组(P<0.05)。治疗4周后,治疗组血红蛋白[(136±12.25)g·L^(-1)]及血细胞比容[(36.87±5.12)]与对照组血红蛋白[(90.60±12.26)g·L^(-1)]及血细胞比容[(26.35±3.28)]比较,差异有统计学意义(P<0.05)。治疗组疗后KPS评分较对照组显著提高,表明患者生活质量明显改善(P<0.05)。治疗组与对照组各有1例患者发生血压升高,差异无统计学意义(P>0.05)。结论:重组人促红细胞生成素治疗胃肠道恶性肿瘤患者化疗后相关性贫血的疗效好,贫血纠正快,能够保证化疗正常进行,且不良反应发生率低,值得临床应用。Objective： To evaluate the efficacy and safety of recombinant human erythropoietin （rhEPO） in the treatment of chemotherapy-induced anemia in patients with gastrointestinal cancer. Methods ： Eighty patients with bone marrow supression after chemotherapy for gastrointestinal malignant tumor were divided into two groups by random number table according to their conditions. The treatment group was treated with recombinant human erythropoietin and iron preparations, while the control group only received iron preparations. The changes of hemoglobin, red blood cells, KPS score and adverse reactions were observed. Results： The clinical effective rates of the treatment group and the control group were 97.5% and 25% , respectively, for which the treatment group was statistically significantly higher than the control group （P 〈 0.05）. After 4 weeks of treatment, the hemoglobin [ （136 ±12.25） g. L-1 ] and hematoerit [ （36.87 ±5. 12） ] of the treatment group had statistically significant difference with those of the control group [ （90.60± 12.26） g. L-1 and （26.35 ± 3.28） ] （ P 〈 0.05 ）. The KPS score was significantly im-proved after treatment compared between the two groups, which showed that the quality oflife of patients improved, and the two groups had statistical significance （P 〈 0.05）. There was 1 case of elevated blood pressure in the treatment group and the control group respectively, but the difference was not statistically significant （P 〉 0.05）. Conclusion： Recombinant human erythropoietin induced anemia in patients with gastrointestinal malignancies rapidly, thus the incidence of adverse reactions is low. It is worthy of clinical application .

关 键 词：重组人促红细胞生成素 替吉奥胶囊 奥沙利铂 胃肠道恶性肿瘤 肿瘤相关性贫血 

分 类 号：R979.1[医药卫生—药品]